跳至主要内容
临床试验/NCT00040001
NCT00040001已完成2 期

Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation

Aderis Pharmaceuticals1 个研究点 分布在 1 个国家开始时间: 2002年6月20日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
试验地点
1

研究概览

简要总结

This study is designed to evaluate the safety of DTI-0009 in patients with atrial fibrillation and to find the dose of DTI-0009 that lowers heart rates in patients with atrial fibrillation with rapid ventricular response.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Primary diagnosis of atrial fibrillation with rapid ventricular response of any duration as documented by an ECG

排除标准

  • •Presence of other significant cardiac disease or history of significant neurological, hepatic,cardiovascular, renal, gastrointestinal, thyroid, respiratory, rheumatologic, or hematologic disease or impairment that in the investigator's judgment is serious enough to preclude the patient from safely participating in the study

研究者

发起方
Aderis Pharmaceuticals
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Safety and Efficacy Study of an A1-Adenosine... | 临床试验